In the latest trading session, Moderna (MRNA) closed at $33.86, marking a -5.66% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.01%. Meanwhile, the Dow ...

Moderna MRNA shares soared 10.9% in the last trading session to close at $35.66. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey ...

The company’s portfolio includes two products: Covid-19 vaccine and RSV vaccine (approved only in May 2024). However the company does have a promising pipeline. Moderna has shown promising clinical ...

Moderna Inc (NASDAQ:MRNA) shares are trading lower on Friday afternoon, giving back a portion of the gains seen on Thursday. Here’s what investors need to know. What To Know: The stock spiked on ...

Get the latest Moderna (MRNA) stock analysis: balanced risk-reward, new vaccine launches, and pipeline insights. See why we ...

Multiple analysts have issued price targets for $MRNA recently. We have seen 10 analysts offer price targets for $MRNA in the last 6 months, with a median target of ...

Moderna (MRNA) stock is climbing 8% after the drug maker won a key court case and its CEO bought shares on the open market. MRNA’s Court Victory A German court ruled that BioNTech (BNTX) and Pfizer ...

In early January 2026, Moderna filed for marketing authorization of its investigational seasonal influenza vaccine mRNA-1010 in the US, EU, Canada, and Australia for adults aged 50 and older, ...

Moderna (MRNA) has been quietly grinding higher, with the stock up roughly 11% over the past month and 12% in the past 3 ...